In what may be the smallest double-blind, placebo-controlled clinical trials on record, researchers have shown that treating two individuals with drugs aimed at raising brain levels of glycine improved their psychotic symptoms.

A research team at the University of New Mexico (UNM), Albuquerque, is moving forward with the development of a vaccine against tauopathies, a neurodegenerative class of diseases that includes Alzheimer's disease, but while promising in the lab, it could take a decade to get an actual vaccine to market.